<DOC>
	<DOCNO>NCT00821080</DOCNO>
	<brief_summary>This study evaluate combination drug call sirolimus vandetanib treat glioblastoma . Sirolimus approve use patient undergo organ transplant . Sirolimus work suppress immune system body reject transplant organ . Vandetanib investigational drug try find high safe dose vandetanib sirolimus give safely .</brief_summary>
	<brief_title>Vandetanib Sirolimus Patients With Recurrent Glioblastoma</brief_title>
	<detailed_description>- Vandetanib give participant tablet form . The dose take depend upon enrol study . The doctor inform dose many tablet take . - Sirolimus also give participant tablet form . The dose take depend upon enrol study . The dose first day high dose take every day . - Participants also give Bactrim , one double-strength table three time week ( Monday , Wednesday , Friday ) help prevent participant get type pneumonia call pneumocystis pneumonia . - The following test procedure perform participant begin take study drug every 4 week cycle : Physical exam ; medical history ; question side effect ; tumor assessment MRI CT ( every cycle ) ; Mini-Mental Status exam ( MMSE ) ; ECG ( week 1 , 2 , 4 , 8 , 12 , every 3 month thereafter ) ; blood pressure ; blood test urine test . - Participants research study maximum 12 month .</detailed_description>
	<mesh_term>Glioblastoma</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<criteria>Histologically confirm glioblastoma point disease course All patient must receive prior standard therapy include resection feasible , radiation temozolomide May receive 3 few chemotherapy biotherapy systemic regimen . Gliadel wafer therapy count regimen . Patients may receive prior antiVEGF , antiEGF therapy mTOR inhibitor . Lab value outline protocol Must recover immediate postoperative period must maintain stable decrease corticosteroid regimen least 3 day prior start treatment Must recover possible complication prior chemotherapy period 2842 day since last treatment . Patients must least 4 week nonnitrosourea chemotherapy 6 week nitrosourea chemotherapy . Patients must least 1 week use noncytotoxic therapy Must least 3 month completion radiation radiosurgery Must document progression disease MRI scan use Macdonald criterion KPS 60 great MiniMental Status Examination ( MMSE ) Score &gt; 15 18 year age old All female participant childbearing potential must negative pregnancy test prior enrollment Evidence severe uncontrolled systemic disease concurrent condition Investigator 's opinion make undesirable patient participate trial would jeopardize compliance protocol Clinically significant cardiovascular event within 3 month entry ; presence cardiac disease , opinion Investigator , increase risk ventricular arrhythmia History arrhythmia symptomatic require treatment asymptomatic sustain ventricular tachycardia . Atrial fibrillation , control medication NOT exclusion Previous history QTc prolongation result medication require discontinuation medication Congenital QTc syndrome 1st degree relative unexplained sudden death 40 year age Presence leave bundle branch block ( LBBB ) QTc Bazett 's correction unmeasurable 480 great msec screen ECG Any concomitant medication may cause QTc prolongation , induce Torsades de Pointes induce CYP3A4 function Hypertension control medical therapy Currently active diarrhea may affect ability patient absorb vandetanib . Specifically , patient diarrhea CTCAE v3.0 grade III exclude Women currently pregnant breastfeed Previous current malignancy histology within last 5 year , exception cervical carcinoma situ adequately treat basal cell squamous cell carcinoma skin Receipt investigational agent within 30 day prior commence study treatment Any unresolved toxicity great CTC grade 1 previous anticancer therapy Major surgery , include craniotomy tumor resection , within 4 week incompletely heal surgical incision start study therapy . Stereotactic biopsy tumor within 2 week start therapy Patients enzymeinducing antiepileptic ( EIAED ) drug therapy Patients unable undergo MRI evaluation prior potential enrollment Patients , opinion treat neurooncologist , significant intratumoral peritumoral hemorrhage evident pretherapy MRI Patients history woundhealing disorder , advance coronary disease , recent history ( &lt; 1 year ) peptic ulcer disease Patients serious chronic liver function abnormality uncontrolled hyperlipidemia Patients unable treated medication PCP prophylaxis Patients document allergy sirolimus Patients severely immunosuppressed Current anticoagulation NOT criterion exclusion</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>vandetanib</keyword>
	<keyword>sirolimus</keyword>
	<keyword>recurrent glioblastoma</keyword>
</DOC>